Chemotherapy-free Treatment of Ph-Positive ALL
Mené sur 236 patients adultes atteints d'une leucémie lymphoblastique aiguë Ph+ (âge médian : 55 ans ; durée médiane de suivi : 23,7 mois), cet essai randomisé évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité de deux traitements de première ligne, l'un combinant ponatinib et blinatumomab, l'autre combinant imatinib et chimiothérapie
It would be rare for anyone who has undergone intensive, multicycle, multiagent chemotherapy followed by allogeneic hematopoietic stem-cell transplantation to agree with Nietzsche’s personal view that “Out of life’s school of war, what does not kill me, makes me stronger.” Even though our past approaches to treating patients with the aggressive, life-threatening blood cancer BCR::ABL1 (Philadelphia chromosome) acute lymphoblastic leukemia (Ph-positive ALL) were sometimes curative, such treatment created numerous harms for the patients. Many lost their lives to therapy. In this issue of the Journal, the GIMEMA ALL2820 trial1 — representing the culmination of many years of work by Chiaretti (...)
New England Journal of Medicine , éditorial, 2026